Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.66 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.38 |
| ▸ | TSPO | P30536 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765965 | 0.93 | SIGMAR1 (0.61) | SIGMAR1CHRM5CHRM3KDM4EMDM2 | |
| SCHEMBL11697620 | 0.85 | SIGMAR1 (0.88) | SIGMAR1CHRM5CHRM3KDM4EMDM2 | |
| SCHEMBL665674 | 0.83 | SIGMAR1 (0.61) | SIGMAR1CHRM5CHRM3KDM4EMDM2 | |
| SCHEMBL20605092 | 0.82 | KDM4E (0.50) | SIGMAR1KDM4EMDM2ALDH1A1KMT2A | |
| SCHEMBL7376521 | 0.81 | SIGMAR1 (0.85) | SIGMAR1CHRM5CHRM3 | |
| SCHEMBL6039643 | 0.80 | KDM4E (0.49) | SIGMAR1KDM4EMDM2ALDH1A1KMT2A | |
| SCHEMBL29700458 | 0.80 | KDM4E (0.53) | SIGMAR1KDM4EMDM2ALDH1A1KMT2A | |
| SCHEMBL5863 | 0.80 | SIGMAR1 (0.56) | SIGMAR1CHRM5CHRM3KDM4EALDH1A1 | |
| SCHEMBL15733359 | 0.80 | SIGMAR1 (0.64) | SIGMAR1CHRM5CHRM3KDM4EMDM2 | |
| SCHEMBL12629398 | 0.80 | SIGMAR1 (0.54) | SIGMAR1CHRM5CHRM3KDM4EMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3042900-B1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-09-23 | — | — | EP | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| EP-3042900-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | Fujifilm Corporation (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-4068070-A | ANGINA PECTORIS | FUJI CHEMICAL INDUSTRY CO., LTD. (JA) | 1978-01-10 | — | — | US | disclosed |
| US-3962247-A | ANGINA PECTORIS | FUJI CHEMICAL INDUSTRY CO., LTD. (JA) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | SIGMAR1 427/4885CHRM5 84/4885CHRM3 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.